Gabelli Funds LLC trimmed its stake in AstraZeneca plc (NYSE:AZN) by 24.6% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 98,000 shares of the company’s stock after selling 32,000 shares during the period. Gabelli Funds LLC’s holdings in AstraZeneca were worth $4,368,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of AZN. Manchester Financial Inc. bought a new position in shares of AstraZeneca in the 2nd quarter valued at approximately $25,000. Oakworth Capital Inc. raised its stake in shares of AstraZeneca by 141.0% in the 2nd quarter. Oakworth Capital Inc. now owns 964 shares of the company’s stock valued at $40,000 after acquiring an additional 564 shares in the last quarter. San Francisco Sentry Investment Group CA raised its stake in shares of AstraZeneca by 37.6% in the 2nd quarter. San Francisco Sentry Investment Group CA now owns 967 shares of the company’s stock valued at $40,000 after acquiring an additional 264 shares in the last quarter. Winslow Evans & Crocker Inc. raised its stake in shares of AstraZeneca by 58.6% in the 2nd quarter. Winslow Evans & Crocker Inc. now owns 1,050 shares of the company’s stock valued at $44,000 after acquiring an additional 388 shares in the last quarter. Finally, Venturi Wealth Management LLC bought a new position in shares of AstraZeneca in the 3rd quarter valued at approximately $46,000. 17.54% of the stock is currently owned by institutional investors and hedge funds.
In other AstraZeneca news, major shareholder Plc Astrazeneca bought 425,000 shares of the stock in a transaction on Monday, October 7th. The shares were purchased at an average price of $19.00 per share, with a total value of $8,075,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
A number of research analysts recently weighed in on AZN shares. Goldman Sachs Group reissued a “sell” rating on shares of AstraZeneca in a research note on Thursday, October 24th. Zacks Investment Research downgraded AstraZeneca from a “strong-buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research note on Thursday, October 3rd. DZ Bank downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, October 22nd. Finally, HSBC reaffirmed a “sell” rating on shares of AstraZeneca in a report on Thursday, October 17th. Four research analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $46.53.
AZN opened at $47.26 on Friday. The firm has a market capitalization of $122.79 billion, a P/E ratio of 27.32, a price-to-earnings-growth ratio of 1.53 and a beta of 0.48. The stock’s 50 day moving average price is $45.32 and its two-hundred day moving average price is $42.22. The company has a quick ratio of 0.70, a current ratio of 0.92 and a debt-to-equity ratio of 1.29. AstraZeneca plc has a 12-month low of $35.30 and a 12-month high of $49.22.
AstraZeneca (NYSE:AZN) last released its earnings results on Thursday, October 24th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.45 by $0.05. The firm had revenue of $6.13 billion for the quarter, compared to analyst estimates of $6.07 billion. AstraZeneca had a return on equity of 38.63% and a net margin of 8.42%. The company’s revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.71 EPS. As a group, analysts anticipate that AstraZeneca plc will post 1.81 earnings per share for the current year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Initial Coin Offerings entail a high degree of risk
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.